|
|
|
| Clinical Efficacy and Safety of Intravitreal Injection of Compaccip in the Treatment of Choroid Neovascularization Secondary to Pathological Myopia |
| CHANG Caixia, WANG Dengting, ZHOU Xiaoming, et al |
| Gansu Central Hospital of Rehabilitation, Gansu Lanzhou 730000, China |
|
|
|
|
Abstract Objective: To explore clinical efficacy and safety of intravitreal injection of Compaccip in the treatment of choroid neovascularization secondary to pathological myopia. Methods: A total of 100 CNV patients from July 2017 to July 2019 were included and divided into research group(n=50)which received conventional western medicine treatment,and control group (n=50),which had intravitreal injection of Compaccip. Before and 3 months after treatment the best corrected visual acuity (BCVA) was applied to evaluate vision of patients,and also conducted were the observation of CNV area before and after treatment,the analysis of changes in intraocular pressure (IOP) and calculation of the thickness of macular central (CMT),and the measurement and comparison of the levels of vascular endothelial growth factor (VEGF) and C-reactive protein of the two groups. Results: 3 months after treatment,BCVA of patients in both groups was increased compared with that before treatment,and the difference was statistically significant (P<0.05),but there was no statistically significant difference (P>0.05) between the two groups. 3 months after treatment,the visual acuity of both groups increased,but there was no statistically significant difference between the two groups (P>0.05).Compared with those before treatment,the CNV area,IOP,CMT,VEGF and CRP in the two groups decreased significantly (P<0.05),but there was no statistically significant difference between the two groups (P>0.05).Compared within the two groups,there was no statistically significant difference in complications and recurrence rates (P>0.05). Conclusion: The effect of intravitreal injection of Conbercept in the treatment of pathological myopia CNV is equivalent to that of Ranibizumab. It can effectively reduce inflammatory indicators,with fewer complications and recurrences,and high safety.
|
|
|
|
|
|
[1] Lai TYY,Staurenghi G,Lanzetta P,et al.Efficacy and safety ofranibizumab for the treatment of choroidal neovascularization due touncommon cause:twelve-month results of the Minerva Study[J].Retina,2018,38(8):1464~1477.
[2] Milani P,Pellegrini M,Massacesi A,et al.Is ellipsoid zone integrityessential for visual recovery in myopic neovascularization after anti-VEGF therapy[J]. Graefe's Arch Clin Exp Ophthalmol,2017,255(9):1713~1720.
[3] 余岚,陈长征,苏钰,等.玻璃体腔注射康柏西普治疗特发性脉络膜新生血管的疗效观察[J].中华眼底病杂志,2016,32(1):12~16.
[4] 孙磊,陶勇.玻璃体腔注射抗VEGF药物对MCNV和ICNV治疗前后BCVA及mfERG的影响[J].国际眼科杂志,2017,17(7):1245~1248.
[5] Rinaldi M,Semeraro F,Chiosi F,et al.Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia[J]. Graefe's Arch Clin ExpOphthalmol,2017,255(3):529~539.
[6] 刘华妮,李明新.康柏西普与雷珠单抗对RF/6A细胞增殖和迁移影响的比较[J].基础医学与临床,2017,37(1):87~93.
[7] 黄鹤龄,方一惟,陈欣华,等.复方血塞通联合康柏西普治疗病理性近视脉络膜新生血管的疗效[J].国际眼科杂志,2017,17(6):1167~1170.
[8] Yan M,Huang Z,Lian HY,et al.Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia[J].Acta Ophthalmol,2019,97(5):813~814. |
|
|
|
2021, Vol. 27 
